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While antibodies play an important protective role during dengue virus infection, they have also been linked to
more severe clinical outcomes. In this issue of Cell Host & Microbe, Zellweger and colleagues (Zellweger
et al., 2010) describe the development of a murine model of antibody-enhanced dengue virus infection
that provides a formal link between immune enhancement and severe disease.Dengue virus (DENV) is a member of the
Flavivirus genus that infects an estimated
50 million inhabitants of tropical and sub-
tropical regions of our planet each year,
with 2.5 billion people at risk. Four anti-
genically related DENV serotypes are
transmitted to humans through the bite
of Aedes aegypti and albopictus mosqui-
toes, each capable of causing disease.
While a large fraction of DENV infections
are asymptomatic, clinically apparent
primary DENV infections typically result
in a self-limiting illness (dengue fever [DF])
characterized by high fever, headache,
retro-orbital and muscle pain, and rash.
Under some circumstances, DENV infec-
tion results in a severe, potentially fatal
illness involving increased vascular per-
meability, decreased platelet count, hem-
orrhage, and shock (Halstead, 2007).
Several lines of evidence support a link
between a pre-existing DENV immune
response and severe outcomes of infec-
tion (Halstead, 2003). Prospective clinical
studies indicate that dengue hemorrhagic
fever/dengue shock syndrome (DHF/
DSS) most commonly occurs in individ-
uals experiencing a secondary infection
with a heterologous serotype of virus.
Severe disease has also been observed
following primary infection of infants of
DENV-immune mothers.
Antibodies play an important role in
protection against flaviviruses and can
exert their antiviral activity by directly
neutralizing virus infection and via effector
functions mediated by the Fc portion of
the antibody molecule (Pierson et al.,
2008). Flaviviruses are spherical envel-
oped virions covered by a dense ordered
array of envelope (E) proteins. Theseproteins orchestrate several aspects of
the virus life cycle, including virus attach-
ment, entry, and fusion with membranes
of the host cell. Antibodies that recognize
epitopes on the E protein are a major
component of the humoral response. To
date, more than 15 structurally distinct
epitopes have been identified on the E
proteins of flaviviruses that are recog-
nized by antibodies. Importantly, some
of these epitopes, such as the DII-fusion
loop (DII-FL), are conserved among
flaviviruses and can be recognized by
heterologous cross-reactive antibody re-
sponses. Eliciting a protective antibody
response is a major goal of ongoing ef-
forts to develop safe and effective DENV
vaccines.
DENV-reactive antibodies have also
been implicated in the development of
severe clinical manifestations of DENV
infection. Antibody-dependent enhance-
ment of infection (ADE) describes an
increase in the efficiency of virus infection
in the presence of nonneutralizing con-
centrations of virus-reactive antibody
(Halstead and O’Rourke, 1977). In this
context, antibodies may increase the effi-
ciency of virus attachment and infection
through interactions with Fcg receptors
expressed on the surface of target cells.
ADE has been suggested to play a critical
role in promoting severe clinical out-
comes of DENV infection by facilitating
access to Fcg receptor-bearing cells
otherwise inefficiently infected in the
naive host (Halstead, 2003). In support
of this hypothesis, infants with nonneutr-
alizing concentrations of passively ac-
quired, maternal anti-DENV antibody are
at increased risk for severe manifesta-Cell Host & Microbe 7tions of disease following primary DENV
infection (Kliks et al., 1988). In addition,
administration of antibody to primates
has been shown to increase viral load,
although enhanced disease was not ob-
served in these studies (Goncalvez et al.,
2007). However, the precise mechanisms
and circumstances that combine to pro-
mote enhanced DENV disease remain
unclear. Despite significant effort, the
development of a suitable small animal
model of ADE and enhanced disease
has been elusive until now.
In this issue of Cell Host and Microbe,
Zellweger and colleagues describe a mu-
rine model of antibody-enhanced DENV
replication and disease that mimics key
clinical features of severe DENV infection
in humans (Zellweger et al., 2010). Similar
findings are reported in a parallel study
appearing in PLoS Pathogens (Balsitis
et al., 2010). Passive transfer of DENV-
reactive antibody into interferon recep-
tor-deficient AG129 mice significantly
increased mortality following challenge
with relatively low dose of a previously
characterized mouse-adapted DENV
(Shresta et al., 2006). Antibody-exacer-
bated disease was accompanied by a
systemic increase in viral load and was
characterized by elevated levels of cyto-
kines (TNF-a, IL-6, and IL-10), thrombo-
cytopenia, and increased vascular
leakage, features that are hallmarks of
severe DENV illness in humans (Halstead,
2007). In contrast, control animals not
only survived for longer periods postchal-
lenge but also exhibited distinct symp-
toms (no vascular leakage) (Figure 1).
The ability to enhance disease was anti-
body concentration dependent. Antibody, February 18, 2010 ª2010 Elsevier Inc. 85
Figure 1. A Small-Animal Model
of Antibody-Enhanced Disease: A New
Approach for Investigating Correlates
of Protection and Severe Disease during
DENV Infection
In vitro studies suggest that neutralization and
enhancement are two phenomena related by the
number of antibodies bound to the virion. In agree-
ment, antibody/serum titration studies using the
murine model described by Zellweger et al. (2010)
and Balsitis et al. (2010) demonstrate that antibody
can protect from infection, or enhance disease,
depending on the circulating concentration. It
remains unclear how in vitro assays correlate with
in vivo outcomes, and how this varies as a function
of the isotype, specificity, and the mechanism of
neutralization of the antibody or serum assayed.
Future studies using the AG129 antibody-depen-
dent severe disease model will enable novel
approaches to investigate correlates of protection
and severe outcomes.
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Previewsthat was protective at one dose enhanced
infection at lower concentrations, paralle-
ling the observation in vitro that neutrali-
zation and ADE are phenomena related
simply by the number of antibodies
bound to the virion (Pierson et al., 2008).
In this model, enhanced disease required
interactions between DENV-reactive
antibody and Fcg receptors on target
cells; neither Fab fragments nor intact
antibodies genetically engineered to lack
the ability to bind Fc receptors were
capable of enhancing disease (Balsitis
et al., 2010).86 Cell Host & Microbe 7, February 18, 2010While the presence of DENV-reactive
antibody increased viral load in multiple
tissues and cell types, including myeloid
cells (dendritic cells and macrophages)
thought to be natural targets of DENV
infection in humans (Jessie et al., 2004),
the most dramatic and rapid increases in
viral burden were observed in the liver
and small intestine. To explore this in
greater detail, Zellweger et al. (2010)
investigated the cell types involved in
ADE in the liver. Using multiple ap-
proaches, they found that DENV-reactive
antibody dramatically increased infection
of CD45CD31+ liver sinusoidal endothe-
lial cells (LSECs). As these cells appeared
quite refractory to infection in vivo in the
absence of antibody, the authors suggest
that antibody-mediated access to this
target cell type plays an important early
role in establishing the enhanced replica-
tion and disease in this model. While this
is certainly an interesting possibility that
merits further study, an important consid-
eration when interpreting this finding in
the context of human disease is the
genetic background of the mouse strain
used in these studies. Interferons play a
critical role in the host response to flavivi-
rus infection. Previous studies with the
flavivirus, West Nile virus, reveal an ex-
panded cellular and tissue tropism in in-
terferon receptor-deficient mice (Samuel
and Diamond, 2005). It remains possible
that the cell types critical for the produc-
tion of cytokines and other factors that
play a key role in enhanced pathogenesis
will differ in the context of an immunolog-
ically competent host.
While some features of antibody-
enhanced disease in this model differ
from the severe outcomes experienced
by humans, such as the temporal relation-
ship between viremia and disease, the
development of a system that directly
links immune enhancement and disease
is an important first step that will be of
considerable utility. Insight into the struc-
tures of flaviviruses and how virions
interact with antibody (and in what num-
bers) have allowed for significant ad-
vances in our understanding of the mech-
anisms of neutralization in quantitative
terms (Pierson et al., 2008). However, until
now, evaluating the relevance and accu-
racy of the concepts and models arising
from in vitro studies has not been possible
in vivo. This model enables new ap-
proaches in several areas. First, the abilityª2010 Elsevier Inc.to examine the functional properties of
anti-DENV antibodies of varying speci-
ficity, affinity, and isotype in a model
where ADE and enhanced disease is
possible will advance our understanding
of the desirable features of protective
antibody and antibody responses, as
well as those that may contribute to se-
vere disease (Figure 1). For example, the
epitopes recognized by enhancing anti-
bodies present in polyclonal heterologous
immune sera have not been identified
using functional approaches, nor have
the specificities responsible for lifelong
protection by reinfection by homologous
DENV. Passive transfer of epitope-de-
pleted serum into this model should be
insightful. Second, this model is suited
for the testing and development of antivi-
rals or immunotherapeutics designed to
be administered to those experiencing
severe manifestations of DENV infection.
Of interest, Balsitis and colleagues (Balsi-
tis et al., 2010) employed this model to
provide proof of principle that antibody
molecules engineered to lose interaction
with Fcg receptors have therapeutic
potential. The development of a small-
animal model for ADE is a significant
advance that will undoubtedly stimulate
research into many areas of DENV patho-
genesis and the antiviral humoral immune
response.
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